PACUPod is your trusted source for evidence-based insights tailored to advanced clinical pharmacists and physicians. Each episode dives into the latest primary literature, covering medication-focused studies across specialty pharmacy, and many more. We break down study designs, highlight key findings, and objectively discuss clinical implications—without the hype—so you stay informed and ready to apply new evidence in practice. Whether you’re preparing for board certification or striving for excellence in patient care, PACUPod helps you make sense of the data, one study at a time.
Britany: Welcome back to PACULit, everyone. Today, we’re diving into an integrated safety analysis on abrocitinib for moderate-to-severe atopic dermatitis, focusing on long-term safety across age groups. Seth, atopic dermatitis remains a significant clinical challenge globally, right?
Seth: Absolutely, Britany. AD affects up to 20% of children and about 3% of adults worldwide. Moderate-to-severe cases often require systemic therapies because topical treatments aren’t enough. The disease impacts quality of life and is linked to comorbidities like infections and cardiovascular risks.
Britany: That’s where JAK1 inhibitors like abrocitinib come in. Prior studies, including Simpson et al. 2023, showed abrocitinib’s efficacy, especially at 200 mg, with a favorable short-term safety profile. But what about long-term safety across ages?
Seth: That’s the gap this integrated analysis by Cork and colleagues addresses. Older adults, 65 and above, have been underrepresented in trials but may be more vulnerable to adverse events like infections, malignancies, cardiovascular issues, and hematologic abnormalities. Adolescents, 12 to under 18, also need more safety data given their developmental stage.
Britany: This study pooled data from multiple JADE trials, including phase 2 and 3 RCTs and extensions, totaling 3,802 patients with moderate-to-severe AD. The cumulative exposure was over 5,200 patient-years, which is robust.
Seth: They stratified patients into four age groups: adolescents (12 to <18), young adults (18 to <40), middle-aged adults (40 to <65), and older adults (≥65). Abrocitinib was given at fixed doses of 100 mg or 200 mg daily, with some patients having variable dosing.
Britany: Important to note, this integrated dataset didn’t include a placebo comparator. The focus was on treatment-emergent adverse events (TEAEs), especially serious adverse events, serious infections, herpes zoster, malignancies, cardiovascular events, and hematologic abnormalities.
Seth: The median follow-up extended beyond one year for many patients, though with some variability. Incidence rates were calculated per 100 patient-years, stratified by age and dose, but no formal hypothesis testing was done since this was a post hoc stratification.
Britany: Key findings: older adults had numerically higher incidence rates for serious adverse events, serious infections, herpes zoster, thrombocytopenia, lymphopenia, nonmelanoma skin cancer, other malignancies, major cardiovascular events, and venous thromboembolism compared to younger groups.
Seth: The highest numerical risk was in older patients treated with 200 mg abrocitinib, underscoring the need for careful dose selection and monitoring in this population.
Britany: Conversely, adolescents had the lowest rates of these TEAEs of special interest, supporting abrocitinib’s safety in this younger group with standard monitoring.
Seth: This aligns with Paller et al.’s integrated analysis, which confirmed a favorable long-term safety profile in adolescents. It’s reassuring for clinicians treating younger patients.
Britany: Clinically, pharmacists and prescribers should be vigilant when dispensing abrocitinib to older adults. Individualized dose selection, counseling on infection risks—especially herpes zoster—malignancy monitoring, and cardiovascular risk assessment are essential.
Seth: And don’t forget hematologic monitoring. The study noted increased thrombocytopenia and lymphopenia in older adults, so regular lab assessments should be part of management.
Britany: The study’s comprehensive safety assessment including hematologic parameters is a strength, helping clinicians anticipate and manage adverse effects proactively.
Seth: Another strength is the large pooled sample size and extensive exposure time, enhancing safety data reliability. However, post hoc age stratification could introduce bias and limits causal inferences.
Britany: Also, the variable-dose cohort design complicates direct dose-response interpretations since some patients switched doses, blurring safety signals for specific doses.
Seth: True, and follow-up beyond one year was limited for some participants, so very long-term safety remains uncertain.
Britany: Regarding mechanisms behind age-related differences, older adults generally have immunosenescence, which could explain higher infection and malignancy rates.
Seth: Their cardiovascular risk is also inherently higher, so increased major cardiovascular events and venous thromboembolism might reflect both drug effects and baseline risk.
Britany: That’s why dose individualization is important. The 200 mg dose, while more efficacious, may carry increased risks in older adults. Lower doses or alternative therapies might be preferable depending on comorbidities.
Seth: Adolescents seem to tolerate 200 mg well, which is encouraging. Their immune systems are more robust, and developmental factors don’t appear to increase adverse event risk significantly.
Britany: Another clinical pearl: herpes zoster vaccination before starting abrocitinib in older adults is important, given the increased incidence in this group.
Seth: Prophylactic strategies like vaccination can mitigate infection risks. Clinicians should also be aware of potential drug interactions, especially with other immunosuppressants or medications affecting platelet counts.
Britany: For example, concomitant use of anticoagulants or antiplatelet agents with abrocitinib could increase bleeding risk if thrombocytopenia develops.
Seth: And since abrocitinib is metabolized primarily by CYP enzymes, drugs that inhibit or induce these enzymes could alter plasma levels, impacting efficacy and safety.
Britany: In practice, thorough medication reconciliation and patient education are vital. Regular lab monitoring and dose adjustments optimize outcomes.
Seth: The study highlights the need for further research comparing abrocitinib with other JAK inhibitors or biologics, especially stratified by age, to better understand relative safety profiles.
Britany: Yes, and exploring mechanisms behind age-related differences in adverse event rates could inform future therapeutic strategies and monitoring guidelines.
Seth: Overall, this integrated analysis provides a comprehensive view of abrocitinib’s long-term safety, reinforcing its manageable profile but emphasizing caution in older adults.
Britany: To sum up, abrocitinib remains a valuable oral systemic option for moderate-to-severe atopic dermatitis across ages. Clinicians must tailor dose and monitoring strategies, especially for patients 65 and older.
Seth: For adolescents, the data support safe use with standard monitoring, reassuring for expanding treatment options in this population.
Britany: Thanks for this insightful discussion, Seth. For our listeners, review the full study by Cork et al. in the Journal of Allergy and Clinical Immunology: In Practice, 2025, for detailed data.
Seth: Absolutely, Britany. Staying current with integrated safety analyses helps optimize patient care and anticipate challenges in managing atopic dermatitis.
Britany: That wraps up today’s PACULit update. Thanks for tuning in, and we look forward to bringing you more cutting-edge clinical literature soon.
Seth: Take care, everyone!